NYSEAMERICAN:OGEN Oragenics (OGEN) Stock Price, News & Analysis $0.44 0.00 (-0.23%) Closing price 10/15/2026 04:10 PM EasternExtended Trading$0.44 +0.01 (+2.06%) As of 10/15/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsOwnershipSEC Filings About Oragenics Stock (NYSEAMERICAN:OGEN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Oragenics alerts:Sign Up Key Stats Today's Range$0.43▼$0.4650-Day Range$0.44▼$0.5552-Week Range$0.43▼$1.45Volume11,621 shsAverage Volume27,819 shsMarket Capitalization$1.97 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oragenics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing intranasal medicines for neurological disorders. Its lead product candidate, ONP-002, is being developed as a potential treatment for concussion and mild traumatic brain injury. The company’s intranasal delivery approach is intended to help deliver therapies directly to the brain while avoiding some limitations associated with conventional administration methods. Oragenics has also pursued ONP-001, an intranasal product candidate for glioblastoma, an aggressive form of brain cancer. These programs remain investigational and are not approved for commercial use. The company’s development activities are focused primarily on advancing its neuroscience pipeline through preclinical and clinical research. Historically, Oragenics worked in oral health and infectious disease research. Its earlier activities included the development of probiotic technologies and lantibiotic-based antibiotic candidates, including programs related to oral-care products. The company has since shifted its strategic focus toward intranasal therapeutics for neurological and central nervous system conditions.AI Generated. May Contain Errors. Read More Oragenics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreOGEN MarketRank™: 0.03479973736 of 5 starsOragenics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oragenics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioOragenics has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.23% of the float of Oragenics has been sold short.Short Interest Ratio / Days to CoverOragenics has a short interest ratio ("days to cover") of 24.89, which indicates bearish sentiment.Change versus previous monthShort interest in Oragenics has recently increased by 4.35%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOragenics does not currently pay a dividend.Dividend GrowthOragenics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for OGEN on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oragenics insiders have not sold or bought any company stock.Percentage Held by Insiders16.10% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions18.71% of the stock of Oragenics is held by institutions.Read more about Oragenics' insider trading history. Receive OGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oragenics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OGEN Stock News HeadlinesOragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation ForumSeptember 16, 2026 | globenewswire.comOragenics, Inc.: Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateAugust 30, 2026 | finanznachrichten.deBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing December 8th. | Paradigm Press (Ad)Oragenics Faces NYSE Compliance Challenges Amid Trial ProgressAugust 28, 2026 | tipranks.comOragenics Updates Phase IIa Trial Progress, FDA Regulatory Pathway and NYSE American Listing StatusAugust 28, 2026 | quiverquant.comQOragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing UpdateAugust 28, 2026 | globenewswire.comOragenics Appoints New Chief Financial Officer and LeaderJuly 11, 2026 | theglobeandmail.comOragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now EnrollingJuly 7, 2026 | globenewswire.comSee More Headlines OGEN Stock Analysis - Frequently Asked Questions How have OGEN shares performed this year? Oragenics' stock was trading at $0.78 at the start of the year. Since then, OGEN shares have decreased by 44.1% and is now trading at $0.4360. How were Oragenics' earnings last quarter? Oragenics, Inc. (NYSEAMERICAN:OGEN) posted its earnings results on Thursday, August, 13th. The company reported ($0.57) earnings per share (EPS) for the quarter. When did Oragenics' stock split? Shares of Oragenics reverse split on the morning of Monday, January 23rd 2023.The 1-60 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of Oragenics? Shares of OGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Oragenics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oragenics investors own include Bionano Genomics (BNGO), Jaguar Animal Health (JAGX), Tonix Pharmaceuticals (TNXP), NIO (NIO), Tesla (TSLA), Ocugen (OCGN) and Plug Power (PLUG). Company Calendar Last Earnings8/13/2026Today10/15/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (32m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 OGEN's financial health is in the Red zone, according to TradeSmith. OGEN has been in this zone for over 32 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:OGEN Previous SymbolNYSE:OGEN CIK1174940 Webwww.oragenics.com Phone813-286-7900Fax813-286-7904Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.84 million Net MarginsN/A Pretax MarginN/A Return on Equity-144.22% Return on Assets-112.79% Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual Sales$40 thousand Price / Sales49.16 Cash FlowN/A Price / Cash FlowN/A Book Value$1.94 per share Price / Book0.22Miscellaneous Outstanding Shares4,510,000Free Float3,786,000Market Cap$1.97 million OptionableN/A Beta1.26 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NYSEAMERICAN:OGEN) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersWall Street’s giving up on this trade. I’m not.Major banks have slashed their gold price targets - Morgan Stanley to $4450, JPMorgan to $4500 - after predict...Traders Agency | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredOn Oct 15, AI Could Make Life Very Strange in AmericaWall Street veteran Marc Chaikin, who called the 2020 market crash, says a major shift could unfold starting O...Chaikin Analytics | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
